← SynDRA
NELARABINE
SynDRA canonical compound SYN0023405 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | ADA | POLA1 |
|---|
| Mechanism of action | DNA synthesis inhibitor | T cell inhibitor |
|---|
| Indication | acute lymphoblastic leukemia (ALL) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
Mechanisms of action (all sources)
- DNA synthesis inhibitor
- T cell inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Nucleic Acid Synthesis Inhibitors
- Nucleoside Metabolic Inhibitor
- Antiviral Agents
ATC classes
Cross-references
Synonyms
- ARRANON
- Arranon
- arranon
- nelzarabine
- atriance
- Nelarabina
- Attriance
- Nelzarabine
- 506U
- 506U78
- GW-506U78
- MAY
- NSC-686673
- NSC-755985
- NSC-759876
- Atriance
- ArranonG
- Nelarabine [USAN]
- Nelzarabine [USAN]
- GW506U78
- U78
- Arranon (GlaxoSmithKline)
- Arranon (TN)
- Arranon, Nelarabine
- Atriance (TN)
- GW-506U
- Nelarabine (INN)
- Nelzarabine (USAN)
- O-Methoxydeoxyguanosine
- O-Methylguanosine
- Nelarabine (JAN/USAN)
- 2-Amino-6-methoxypurine arabinoside
- 6'-O-Methylguanosine
- GW 506U78
- NSC 686673
- Nelarabine (Arranon)
- CHEBI:63612
Look up NELARABINE in the interactive SynDRA portal →